TRACON Pharmaceuticals and I-Mab Biopharma to Host Conference Call to Discuss Strategic Partnerships for Multiple Immuno-Oncology Programs
Wednesday, December 5th @ 4:30pm Eastern Time | |
US Investors: | 877-407-9039 |
International: | 201-689-8470 |
Passcode: | 13685586 |
Webcast: | http://public.viavid.com/index.php?id=132472 |
Replays, Available through December 19th: | |
Domestic: | 844-512-2921 |
International: | 412-317-6671 |
Replay PIN: | 13685586 |
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD by corporate partner
About I-Mab
I-Mab is a dynamic and fast-growing global company exclusively focused on developing first-in-class and best-in-class biologics in the areas of immuno-oncology and autoimmune diseases through internal R&D capabilities and global partnerships. I-Mab's pipeline is driven by the company's development strategy to address unmet needs in
Forward-Looking Statements
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON's and I-Mab’s plans to further develop product candidates, potential benefits of the collaborations between TRACON and I-Mab, expectations regarding the timing of regulatory submissions and clinical trials, expected development milestones, I-Mab’s status in becoming a fully-integrated biopharma company. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or I-Mab will be able to make regulatory submissions or complete or initiate clinical trials on expected timelines, if at all; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; the fact that the strategic collaboration agreements are subject to early termination; whether any product candidates are selected to be developed under the strategic collaborations, potential changes in regulatory requirements in
TRACON Company Contact: | TRACON Investor Contact: |
Mark Wiggins | Andrew McDonald |
Chief Business Officer | LifeSci Advisors LLC |
(858) 550‐0780 ext. 236 | 646-597-6987 |
mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
I-Mab Company Contact: | I-Mab Investor Contact: |
Raven Lin | Jielun Zhu |
Vice President of Corporate Development | Chief Financial Officer |
(86) 21 6057‐8033 | (86) 21 6057 5788 |
raven.lin@i-mabbiopharma.com | jielun.zhu@i-mabbiopharma.com |
Source: TRACON Pharmaceuticals, Inc.